Your Position: Home > Journal List > China Medicine > Paper

Mutant prevention concentration of 6 kinds of fluoroquinolones for coagulase negative staphylococcus

( views:511, downloads:0 )
Author:
JING Liang-yan(Department of Respiratory Medicine,Second Hospital Affiliated to Dalian Medical University,Dalian 116023,China)
WANG Hui-ling(Department of Respiratory Medicine,Second Hospital Affiliated to Dalian Medical University,Dalian 116023,China)
XUE Xin(Department of Respiratory Medicine,Second Hospital Affiliated to Dalian Medical University,Dalian 116023,China)
XIE Guang-hong()
Journal Title:
China Medicine
Issue:
Volume 07, Issue 11, 2012
DOI:
10.3760/cma.j.issn.1673-4777.2012.11.045
Key Word:
Mutant prevention concentration;Fluoroquinolones;Coagulase negative staphylococcus

Abstract: Objective To determine the mutant prevention concentration (MPC) of 6 kinds of fluoroquinolones for the clinical isolated coagulase negative staphylococcus,and to compare the 6 kinds of fluoroquinolones.Methods The minimal inhibitory concentrations (MIC) and the mutant prevention concentration (MPC) of ciprofloxacin,levofloxacin,gatifloxacin,cadrofloxacin,moxifloxacin and pazufloxacin were determined with 34 strains of coagulase negative staphylococcus isolated which were sensitive to oxacillin and ciprofloxacin by agar two-fold dilution method and ager plates dilution method.Results For MPC9o,moxifloxacin was the lowest (1 mg/L).Cadrofloxacin,gatifloxacin and pazufloxacin,levofloxacin and ciprofloxacin were the highest among the 6 kinds of fluoroquinolones against coagulase negative staphylococcus which were 32 mg/L; as for MIC90/MPC90,moxifloxacin,cadrofloxacin and gatifloxacin were lower; pazufloxacin,levofloxacin and ciprofloxacin were higher.The comparison of the pharmacokinetics parameter in vivo for the 6 kinds of fluoroquinolones against the 34 strains of coagulase negative staphylococcus showed that MPC90 was less than Cmax for moxifloxacin and cadrofloxacin,and was similar to gatifloxacin.Conclusion Moxifloxacin,cadrofloxacin and gatifloxacin have a lower MPC and narrower mutant selective window with a high ability to restrict the selection of coagulase negative staphylococcus resistant mutants among the 6 kinds of fluoroquinolones against the coagulase negative staphylococcus.

  • [1]汪复.2005中国CHINET细菌耐药性监测结果.中国感染与化疗杂志,2006,6(5):289-295.
  • [2]李朝霞,刘又宁.细菌耐药突变选择窗理论与抗菌药物合理应用.中国药学杂志,2006,41(16):1201-1205.
  • [3]Homma T,Hori T,Sugimori G,et al.Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.Antimicrob Agents Chemother,2007,51 (11):3810-3815.
  • [4]李朝霞,刘又宁,王睿,等.氟喹诺酮类药物对金黄色葡萄球菌及其耐药突变体的耐药性研究.中国临床药理学与治疗学,2006,11 (6):696-701.
  • [5]姚国新,张丽华,汤远亮,等.金黄色葡萄球菌防耐药突变浓度测定方法的影响因素分析.中国药师,2010,13(8):1147-1148.
  • [6]崔俊昌,刘又宁,王睿,等.氟喹诺酮药物浓度对金黄色葡萄球菌耐药突变选择的影响.中国感染与化疗杂志,2006,6(5):309-312.
  • [7]Firsov AA,Smirnova MV,Lubenko IY,et al.Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.J Antimicrob Chemother,2006,58 (6):1185-1192.
  • [8]邱红,彭涛,朱富强.凝固酶阴性葡萄球菌医院感染及耐药性分析.中国医师进修杂志,2006,29(9):5-6,9.
  • [9]尚旭明,王海燕.耐甲氧西林葡萄球菌的耐药性分析.中国基层医药,2008,15(4):623-625.
  • [10]李百丽,何庆云,侯云霞,等.凝固酶阴性葡萄球菌药敏试验结果可信性分析.中国基层医药,2003,10(2):164.
  • [11]黎沾良.应用抗菌药物防治外科感染的进展.中国医师进修杂志:外科版,2007,30(1):18-19.
  • [12]段金菊,刘卓拉.变异选择窗口及防耐药变异浓度.中国药物与临床,2006,6(11):849-851.
  • [13]宋秀杰,刘又宁,王睿.抗菌药物防细菌耐药突变浓度理论及研究进展.药物评价研究,2010,33(1):13-18.
  • [14]梁蓓蓓,王睿,白楠,等.利奈唑胺、万古霉素对甲氧西林耐药的金黄色葡萄球菌的防耐药突变体选择浓度的研究.中国临床药理学与治疗学,2010,15(3):251-254.
  • [15]易洁梅.常用抗菌药物的给药时间与临床合理用药.实用药物与临床,2008,11 (6):368-369.
  • [16]缪佳.氟喹诺酮类药物的临床应用.实用药物与临床,2006,9(4):244-245.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn